Le Lézard
Classified in: Health, Science and technology
Subject: HEALTH

Singleron supports Project Maleth's second mission MALETH II by analyzing biological samples sent to space


COLOGNE, Germany, July 14, 2022 (GLOBE NEWSWIRE) -- Maleth Program is the first space bioscience project led by Professor Joseph Borg of the University of Malta. The second mission under the Maleth Program, or Maleth II, was launched on the July 15th, 2022.

"Maleth II boarded a SpaceX Dragon Spacecraft for the launch as part of Commercial Re-supply mission 25 (CRS25) destined for the International Space Station and will stay in orbit for around 60 days", said Prof. Borg.

Singleron Biotechnologies, a single cell multi-omics company based in Cologne, Germany, proudly supports this exciting project along with the Ministry for Foreign and European Affairs, the Ministry for Education of Malta, and MeDirect ? Malta's first digital Bank. The mission is being facilitated by the Research, Innovation, Development Trust (RIDT) that will be supporting University of Malta students.

The Maleth II biocube will once again be remotely controlled from Malta, by Arkafort Ltd. in collaboration with Prof. Borg and can have real-time telemetry data on the running experiment on board the space station. "Alongside the human skin tissue samples to study microbiome involved in diabetic foot ulcers, is also a yeast sample that forms part of an ongoing mini-project supported by Singleron Biotechnologies to detect at a single cell level all the genetic changes inside the yeast cells when exposed to low earth orbit conditions", explained Prof. Borg.

Singleron is proud to be a partner in this exciting research project from Europe and believes that single cell analysis can be a powerful tool to understand the impact of space trips on biological organisms ranging from yeast to human.

About Singleron
Founded in 2018, Singleron develops and commercializes single-cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic devices, reagents, software analysis and database solutions that facilitate high-throughput single-cell analysis. The company currently has offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 1,600 laboratories in hospitals, research institutes, and pharmaceutical companies.

Media Contact
Shaun Cordes
Email: [email protected]

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/ce9ced24-9d7e-4544-b73b-c489a4cbffa4



These press releases may also interest you

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

19 avr 2024
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: